Wasab……, as we know, a major investor sold down loads of their stock and mentioned publicly that they would repurchase. Well, the shares did that. Now they have made decent profits, they are repurchasing and sentiment is clearly moving up as I’ve stated several times previously since the drop.
There are many of us that have complete confidence in Acadias capabilities to achieve FDA so I tend to follow the smart than the deadshits.
Chartists generally get it right when a stock has movement in turnover and cash, but bios are very difficult to value until they have regulatory approvals and I believe we collectively agree the chances of this are 95-100% chance. I’d back that on the horses…..
Wasa, as I’ve said for 15 years, when this stock has 100 buyers +, we always run north. When we have 200 buyers, we will be cliff climbing.
I’m very confident of an Australian listed stock to be on the radar of fund managers globally within 18 months. This little beauty has limited stock on supply and 75-85% will hold until we are dividend producing or taken out by some giant. I would love to see this stock stay here in Australia and I cannot wait to hear how these girls with the science we are invested in, offer more stabilized lives.
Wasa, Neuren management are world class and I’ve been following them for many years and commend their ability to achieve what they have set out to achieve. They have so much more to deliver, hence why I believe a TO isn’t on the cards.
NEU Price at posting:
$7.71 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)